UK Judge Won't Invalidate Alcon's Glaucoma Treatment Patent

Law360 (April 23, 2021, 5:58 PM EDT) -- A United Kingdom judge on Friday upheld the validity of a glaucoma treatment patent owned by Novartis AG spinoff Alcon, which had been challenged by generic-drug companies.

High Court Judge Richard Meade rejected arguments that Alcon Research LLC's patent was invalid as either obvious or anticipated. Accord-UK Ltd. — which used to be Actavis — and Aspire Pharma Ltd. had already admitted that their generic products infringe, making validity the only question, according to the ruling.

The drug at issue, travoprost, is sold under the brand name Travatan. The eye drops are used to treat high pressure inside the eye, including...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!